Published in Oncogene on April 17, 2003
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet (2010) 4.01
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
Multiple interactions of rad23 suggest a mechanism for ubiquitylated substrate delivery important in proteolysis. Mol Biol Cell (2004) 1.78
The slow Wallerian degeneration protein, WldS, binds directly to VCP/p97 and partially redistributes it within the nucleus. Mol Biol Cell (2005) 1.13
Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer (2007) 1.11
Chediak-Higashi syndrome with early developmental delay resulting from paternal heterodisomy of chromosome 1. Am J Med Genet A (2010) 1.06
A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours. Br J Cancer (2004) 1.04
A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Mol Cancer (2005) 0.99
Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death. BMC Cancer (2005) 0.96
Ubiquitin chain elongation enzyme Ufd2 regulates a subset of Doa10 substrates. J Biol Chem (2010) 0.92
The Cdc48 ATPase modulates the interaction between two proteolytic factors Ufd2 and Rad23. Proc Natl Acad Sci U S A (2011) 0.91
The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatr Surg Int (2012) 0.86
UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation. J Biol Chem (2013) 0.84
Apoptotic cell death in neuroblastoma. Cells (2013) 0.79
Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood (2016) 0.78
E4 ligase-specific ubiquitination hubs coordinate DNA double-strand-break repair and apoptosis. Nat Struct Mol Biol (2016) 0.75
Identification of a novel PEX14 mutation in Zellweger syndrome. BMJ Case Rep (2009) 0.75
Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. Genes Cancer (2016) 0.75
High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A (2010) 1.92
Hereditary myopathy with early respiratory failure associated with a mutation in A-band titin. Brain (2012) 1.92
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest (2011) 1.87
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J (2008) 1.83
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
RNA helicase A is a downstream mediator of KIF1Bβ tumor-suppressor function in neuroblastoma. Cancer Discov (2014) 1.58
Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer (2011) 1.45
Targeted transgene expression in rat brain using lentiviral vectors. J Neurosci Res (2003) 1.40
Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene (2003) 1.33
MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A (2013) 1.33
Foxe3 haploinsufficiency in mice: a model for Peters' anomaly. Invest Ophthalmol Vis Sci (2002) 1.26
Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res (2009) 1.24
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol (2010) 1.24
High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics (2008) 1.22
The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer (2006) 1.18
Frequent detection of human cytomegalovirus in neuroblastoma: a novel therapeutic target? Int J Cancer (2013) 1.16
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res (2004) 1.15
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Dis Model Mech (2012) 1.14
Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer (2012) 1.13
Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics (2002) 1.12
Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J (2009) 1.08
Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res (2010) 1.07
Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics (2011) 1.06
Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis (2013) 1.05
Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res (2007) 1.02
Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. FASEB J (2008) 1.01
The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Mol Cancer (2012) 1.01
MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis (2011) 1.00
Serious illness in childhood: the different threats of cancer and diabetes from a parent perspective. J Pediatr (2004) 0.99
Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer (2011) 0.99
Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res (2013) 0.99
A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Mol Cancer (2005) 0.99
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis. J Inherit Metab Dis (2010) 0.98
Gangliocytes in neuroblastic tumors express alarin, a novel peptide derived by differential splicing of the galanin-like peptide gene. J Mol Neurosci (2006) 0.98
The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. Endocr Relat Cancer (2007) 0.98
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol (2008) 0.97
Embryonal neural tumours and cell death. Apoptosis (2009) 0.97
Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci U S A (2009) 0.96
Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death. BMC Cancer (2005) 0.96
Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res (2010) 0.96
Neuroblastoma tumors with favorable and unfavorable outcomes: Significant differences in mRNA expression of genes mapped at 1p36.2. Genes Chromosomes Cancer (2007) 0.95
Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer. BMC Cancer (2008) 0.94
Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One (2012) 0.93
Genome-wide linkage scan for breast cancer susceptibility loci in Swedish hereditary non-BRCA1/2 families: suggestive linkage to 10q23.32-q25.3. Genes Chromosomes Cancer (2007) 0.93
Expression of trkB in human neuroblastoma in relation to MYCN expression and retinoic acid treatment. Lab Invest (2003) 0.93
The influence of pediatric cancer diagnosis and illness complication factors on parental distress. J Pediatr Hematol Oncol (2008) 0.93
Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion. PLoS One (2013) 0.93
Nuclear accumulation of full-length and truncated adenomatous polyposis coli protein in tumor cells depends on proliferation. Oncogene (2003) 0.92
A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res (2011) 0.92
Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem (2003) 0.92
Stage-dependent expression of PI3K/Akt‑pathway genes in neuroblastoma. Int J Oncol (2012) 0.91
Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo. Int J Cancer (2010) 0.90
Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS One (2012) 0.90
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment. J Natl Cancer Inst (2014) 0.90
Birth characteristics and Wilms tumors in children in the Nordic countries: a register-based case-control study. Int J Cancer (2011) 0.90
Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer (2011) 0.89
Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Int J Oncol (2004) 0.89
Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors. Int J Oncol (2004) 0.89
Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo. Int J Cancer (2009) 0.88
Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer (2006) 0.88
Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes. BMC Med Genomics (2009) 0.88
The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. Oncoimmunology (2013) 0.87
Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol (2003) 0.87
mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer (2008) 0.86
No germline mutations in supposed tumour suppressor genes SAFB1 and SAFB2 in familial breast cancer with linkage to 19p. BMC Med Genet (2008) 0.86
Mutations and sequence variation in the human myosin heavy chain IIa gene (MYH2). Eur J Hum Genet (2005) 0.86
The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A. Int J Oncol (2009) 0.86
NSAIDs in neuroblastoma therapy. Cancer Lett (2005) 0.86
Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis. Int J Oncol (2013) 0.86
Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res (2003) 0.86